Genomic DNA in the nucleus is not present in a naked form, but rather it is associated with small proteins called histones to make a structure termed chromatin. Both DNA and histones are subject to epigenetic regulation; DNA by attachment of methyl group to cytosines (DNA methylation) within a cytosine-phospho-guanine dinucleotide (CpG) and histones by attachment of a number of chemical groups to specific amino acid residues (histone modifications) [4, 6] . These two major epigenetic mechanisms will be considered in further detail in the latter sections.
Non-coding RNAs play an increasingly appreciated and crucial role in epigenetic regulation. Broadly, non-coding RNAs can be divided into long and short species, both of which play prominent but very separate roles in gene regulation. It is now known that only 1% of the mammalian genome codes for proteins, however 70-90% of the entire genome is transcribed at some point during the lifetime to produce a large transcriptome of long non-coding RNAs (lncRNAs) [7, 8] . They are a class of messenger RNA-like transcripts that lack any discernible open reading frame [7] . Long ncRNAs are often poorly conserved, characterized by low copy number, fast turnover rates as well as very long length, ranging from 200 nucleotides up to 100 kilobases, sometimes encompassing a whole chromosome [9] . Due to their length, these RNA species offer the possibility of allele-specific action and targeting of a single location within the genome. This is in contrast to transcription factors or small non-coding RNAs that bind a short DNA sequence which may be repeated numerous times throughout the genome [7] . Although function of many lncRNAs is yet to be illuminated, it is now clear that at least some lncRNAs play a role in processes that lead both to gene activation and repression. This is at least in part achieved by the ability of lncRNAs to guide the catalytic function of chromatin-modifying enzymes to specific sites in the genome, and these complexes then act on chromatin modifications and structure [7, 10] . Currently, there are no lncRNAs with assigned role in liver disease; however, there have been excellent examples within other disease contexts, such as MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), which is a highly conserved lncRNA that regulates metastasis development in lung cancer by activating expression of metastasis-associated genes [11] . Latest studies have shown that antisense oligonucleotides can be used to silence MALAT1 and thus prevent metastatic disease [11, 12] . It will be exciting to learn the potential roles of lncRNAs in liver disease and to find out whether similar antisense silencing regimes may have a therapeutic impact.
MicroRNAs (miR) are a class of short (20-24 nucleotide) noncoding RNAs that regulate gene expression at a post-transcriptional level, through binding to the 3 0 -untranslated region of targeted messenger RNA and causing its degradation or destabilization; alternatively miRs can also effect translational repression [13] . The observed outcome is a modest change in gene expression, widely defined as a ''fine-tuning effect'' [14] . microRNAs and liver disease: intriguing transformation from basic science into clinics
In humans, over 1500 miRs have been identified which in turn target hundreds of genes within numerous biological pathways including liver development, regeneration, and fibrosis. miRNA profiling of distinctive liver diseases including chronic hepatitis C and B, NAFLD (nonalcoholic fatty liver disease), ALD (alcoholic liver disease), and drug-induced liver injury have revealed miRs that are now becoming novel therapeutic targets in various clinical conditions [15, 16] . One of the best examples of such new developments is the discovery of miR-122 role in hepatitis C [17] . miR-122 was shown to facilitate HCV replication by binding to multiple sites in the 5 0 untranslated region of HCV RNA genome and enhances translation of the viral proteins and protect HCV RNA against nucleolytic degradation. In vivo targeting of miR-122 was initially tested in chimpanzees where 12-week intravenous delivery of locked-nucleic-acid-[LNA]-modified complementary oligonucleotide led to depletion of miR-122 and durable reduction in HCV RNA levels as well as lower serum cholesterol levels [19] . Phase I and IIa human trials with Miravirsen (LNAmodified-antimiR-122) have also revealed good safety profiles and tolerability with prolonged reduction in HCV RNA following 18 weeks of treatment [20] . In addition, miR-122 is a mediator of insulin, lipid metabolism, and iron homeostasis. Antagonism of miR-122 reduces cholesterol and LDL levels through affecting hepatic cholesterol and fatty acid biosynthesis genes while inducing b oxidation of fatty acids as well as causing iron deficiency with lower levels of plasma and liver iron [18] . As such, antagonising miR-122 may have multiple beneficial outcomes.
While antagonism of miR-122 shows very encouraging results, two remarkable papers, using germline and liver-specific knockout mice, highlighted some unexpected roles of miR-122 in the liver. Mice with miR-122 deletions had reduced serum cholesterol levels similar to the pharmacological inhibition of miR-122, however, they developed microsteatosis with triglyceride accumulation, steatohepatitis with inflammatory cell recruitment, and elevated pro-inflammatory mediators (IL-6, TNF-a) [21] . Liver fibrosis, via the activation of KLF6 axis, and hepatocellular carcinoma-like tumours were also evident in this phenotype, indicating tumour suppressor properties of miR-122 [22] . With our current knowledge, the reason for the biological distinction between the temporary pharmacological inhibition and the global deletion of miR-122 is not yet known. However, it is likely that our current understanding of the mechanisms by which microRNAs operate in these systems is rather one-dimensional. With further research and improved insight into the ways in which various epigenetic regulatory aspects integrate with one another, we might discover means of manipulating homeostasis as well as disease states.
Histone modifications and liver disease: still on the bench As already stated, DNA inside the nuclei is complexed with histones, forming a structure termed chromatin. The main histone proteins are called histone H2A, histone H2B, histone H3, and histone H4 [4, 6] . The smallest unit of chromatin is a mononucleosome, which consists of 146 base pairs of genomic DNA sequence which is wrapped around an octamer of histones-two copies of each of the histones H2A, H2B, H3, and H4 (Fig. 1) . Histones are small, globular proteins with long 'tails' on one end of the amino acid structure, this being the location of post-translational modifications carried out by numerous enzymes. There are in excess of 60 sites within each octamer of histones that are subject to chemical modification. Modifications include methylation, citrullination, acetylation, phosphorylation, SUMOylation, ubiquitination, and ADP-ribosylation. Combinations of various chemical groups are attached to the histone tails which then form binding sites for protein complexes that are able to affect transcriptional activity of a particular gene. Histone modifications are also able to induce conformational changes in chromatin such to promote transcription or silencing of gene expression in varying degrees. Both of these processes depend on the site, type, and number of chemical groups attached to the histone tails [4, 6, 23] . As there are strings of histone octamers at every 146 base pairs of DNA sequence along the gene, and each one can have a particular set of modifications at one of over 60 sites, the possible combinations that can be achieved are huge [4] . Each combination of histone marks potentially provides a specific recognition site for a protein complex that can alter chromatin structure. In that sense, the histone modifications provide a complex blueprint that regulates transcriptional activity, which is also referred to as the histone code [4] .
In terms of a functional outcome, histone acetylation almost invariably underpins induction of gene transcription; however, methylation of lysine residues within the histone tail can either stimulate (histone 3 lysine 4) or inhibit gene expression (histone 3 lysine 9 or 27 methylation) (please see Fig. 2 for a list of compounds that target histone methylation and acetylation). The acetylation of histones is carried out by two groups of enzymes, histone acetyl transferases (HAT) and histone deacetylases (HDAC) (Fig. 2) . Among histone modifying enzymes, HDACs have received most attention. The role of HDAC3 in circadian regulation, hepatic energy metabolism, and hepatosteatosis has now been clearly demonstrated [24] . HDAC3 negatively regulates lipogenic genes and directs metabolic sources towards gluconeogenesis to maintain normal blood glucose during daytime. In contrast, HDAC3 is significantly downregulated at night, which stimulates lipid synthesis. Interestingly, liver-specific knockdown of HDAC3 leads to the development of marked steatosis, with triglyceride accumulation and ''insulin hypersensitivity''. Similarly, alcohol-induced microsteatosis is associated with reduced HDAC3 expression. Furthermore, alcohol and its metabolite acetate induce acetylation of histones globally in macrophages and hepatocytes, particularly in promoters of pro-inflammatory cytokines [25] .
Pharmacological targeting of histone modifying enzymes, particularly inhibitors of HDACs, constitutes a rapidly growing component of the epigenetic drug market. Two HDAC inhibitors are currently licensed for use in haematological malignancies and similar drugs are in clinical trials for various hematogenous malignancies and solid organ tumors (Fig. 2) [please refer to clinical trials links under Refs. 26, 27] . In vitro and in vivo studies suggest that HDACs are considerably upregulated in chronic liver disease; this led to research using HDAC inhibitors (HDACi) to block myofibroblast generation and fibrogenesis. Laboratory evidence suggests that various HDACi attenuate the activation of hepatic stellate cells and fibrosis in animal models. However, the mechanism of action of the HDACi was not clearly understood and, of note, it is now known that HDACs and their inhibitors have effects on non-histone proteins such as cytoskeleton proteins. For HDACs to be fully exploited for therapeutic purposes, it will be necessary to have a much deeper understanding of their activities and substrates. In addition, we will need histone modifiers with greater specificity; two examples of this approach were recently reported using highly selective inhibitors of EZH2 histone methyltransferase and jumonji H3K27 histone demethylase, which demonstrated antitumorigenic activity in lymphoma cells and modulated macrophage response, respectively [28, 29] .
DNA methylation, methyl-binding proteins and liver disease: astonishing roles -prepare for lift off Methylation of DNA occurs at the 5th carbon in the pyrimidine ring of cytosine nucleotides and most commonly in cytosine phosphoguanine dinucleotides, often referred to as CpGs. Large (longer than 200 bp) and dense (>55%) clusters of CpG sequences are termed CpG islands. Many human gene promoters contain clusters of CpG islands in the unmethylated state; in contrast, most non-promoter CpGs are methylated [30] . The functional role of DNA methylation is relatively complicated, but generally speaking, methylation within the promoter regions ordinarily leads to transcriptional repression, whereas methylation within gene body can exert transcriptional activation. Two main mechanisms have been described for DNA methylation-mediated longterm gene silencing. Methylated DNA can either repress gene expression by recruiting methyl-binding proteins (MeCP2, MBD1-4) that in turn interact with chromatin silencing protein complexes, or it may directly interfere with the binding of transcription factors to their DNA sequence recognition motifs [30] . Methylation of DNA is executed by enzymes known as DNA methyltransferases (Dnmt) using S-adenosyl methionine as the methyl donor [30] . It is not clear how DNA methylation is targeted to a particular region, but it is likely to involve interaction of DNMTs with other chromatin associated factors [30] .
The transdifferentiation of hepatic stellate cells (HSC) into a myofibroblast-like phenotype is a pivotal event in hepatic wound-healing and fibrosis. The dramatic change in phenotype associated with HSC transdifferentiation is underpinned by a global change in gene expression. DNA methylation exists in a number of genes that are expressed at a high level in quiescent HSCs, which are then silenced as the cells activate. At present it is unclear as to whether the DNA methylation pattern of the HSC genome alters with transactivation, however, there is evidence that the way in which the cell ''reads'' the so-called epigenome does change [31] . As HSCs transdifferentiate, they begin to express MeCP2, a DNA methyl-binding protein that is recruited to methyl-CpG marks present on the DNA and upon binding can subsequently recruit chromatin remodeling complexes that silence gene transcription. This type of gene silencing mechanism occurs at the IjBa and PPAR-c genes in activated HSCs, which is required for these cells to acquire their inflammatory and fibrogenic phenotype [31, 32] . In addition to its repressive action, MeCP2 can also act as a transcriptional activator, although the mechanisms by which it achieves this apparently paradoxical effect are not yet clear. A recent report suggested that modification of methyl-CpG to hydroxymethyl-CpG enables MeCP2 to function as a stimulator of transcription [33] . We have previously reported that MeCP2 enhances the expression of other histone modifying enzymes such as the histone methyltransferases EZH2 and ASH1 [31, 34] . These enzymes in turn regulate the attachment of methyl groups to histone H3 lysine 27 (EZH2) and histone H3 lysine 4 (ASH1). Because H3K27 methylation is a transcriptionally repressive mark, EZH2 therefore regulates silencing of target genes, such as PPAR-c [31] . In contrast, methylation of lysine 4 of histone H3 is a signature of actively transcribed genes [6] . During HSC transdifferentiation, ASH1 is recruited to the regulatory regions of the collagen 1A1, TIMP1 and TGFb1 where it facilitates their transcription [34] . Taken together, MeCP2 acts as a pivotal regulator of HSC activation, and it is worth noting that MeCP2 gene deletion or drug mediated EZH2-inhibition attenuates hepatic fibrosis. Rosemarinic acid and baicalin (active ingredient of Yang-Gan-Wan, Chinese herbal preparation) also repress MeCP2-EZH2 relay, thus allowing re-expression of PPAR-c, which in turn prevents hepatic fibrosis [35] .
DNA methylation, MeCP2, EZH2, and ASH1 may be bona fide therapeutic targets for prevention and/or treatment of liver fibrosis. It is very well worth noting the manner in which DNA methylation, methyl binding proteins and enzymes that control histone modifications are involved in crosstalk, and it will be crucial to understand these interactions in order to develop drugs that will target these pathways.
Epigenetic marks are heritable by future generations
Genetic studies exploring the association of single nucleotide polymorphisms and chronic liver diseases created fundamental data regarding the variability of disease development (e.g., NAFLD and PNPLA3) and treatment responses (e.g., hepatitis C and IL28B). However, there remains a significant gap in our understanding of liver patho-physiology. Liver fibrosis is a final common pathway of liver injury irrespective of aetiology, however, it is currently not clear if predisposition to development of fibrosis exists or indeed if existence of disease in previous generations alters such predisposition. We recently described the potential for transgenerational epigenetic transmission of susceptibility traits for liver fibrosis in male rats [5] . Offspring from a lineage of two consecutive generations of ancestors that suffered liver fibrosis, upon injury with the hepatotoxin carbon tetrachloride, developed less fibrosis compared with rats that had no ancestral history of liver disease. The adapted response was characterized by reduced numbers of myofibroblastic HSC, reduced expression of profibrogenic TGFb1, and elevated expression of antifibrogenic PPAR-c and PPAR-a. Interrogation of DNA methylation at the PPAR-c and PPAR-a promoters revealed that ancestral liver disease leads to hypomethylation of these regulatory regions in the livers of offspring. Intriguingly, in a NAFLD cohort, patients with severe fibrosis or cirrhosis had higher levels of PPAR-c promoter DNA methylation as compared to patients with mild fibrosis [5] . This study therefore provides evidence of heritable epigenetic signatures that can be modified in response to injurious stimuli to allow rapid adaptation to limit the fibrogenic response and preserve normal liver architecture. It also raises the exciting possibility of epigenetic screening of liver patients for prognosis of disease progression.
Conclusions
Complex genetic and environmental interactions give rise to the phenotype of an individual. This phenotype is then subject to lifelong change through remodeling of the individual's epigenome. The underlying epigenetic mechanisms can also impact on the course of diseases or chronic conditions that the individual may suffer, such that they can restrict or promote their progression. The challenge now lies in fully understanding the epigenetic mechanisms and their interaction, which is a tall order due to the complexity of the system. With much improved knowledge, we might be able to selectively modulate epigenome through the use of drugs, alteration in diet, or applying other types of interventions in order to alter the course of disease and ageing.
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